Find recruiting clinical trials for Crohn's disease in the UK — from first-line immunosuppressants to advanced biologic and small-molecule therapies. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
Initial management of mild to moderate Crohn's disease
Standard: Aminosalicylates (5-ASAs), Budesonide, or dietary therapy (exclusive enteral nutrition)
When first-line therapy is insufficient or disease is moderate-to-severe
Standard: Azathioprine, 6-Mercaptopurine, Methotrexate, or systemic corticosteroids
For moderate-to-severe disease unresponsive to conventional therapy
Standard: Anti-TNF (Infliximab, Adalimumab), Vedolizumab, or Ustekinumab
After biologic failure — next-generation oral targeted therapies
Standard: Upadacitinib (JAK inhibitor), Risankizumab, or clinical trial
Complex disease including fistulae, strictures, or post-surgical recurrence
Standard: Combination therapy, stem cell therapy (trials), or surgical intervention
A type of inflammatory bowel disease (IBD) causing chronic inflammation of the digestive tract. Affects about 115,000 people in the UK. Can occur at any age but commonly starts between 15-40.
Up to 50% of Crohn's patients don't achieve lasting remission with current treatments. Research into new biologics, JAK inhibitors, microbiome therapies, and stem cell treatments offers hope for better outcomes.
About 20-40% of Crohn's patients develop fistulae — abnormal connections between organs. These are difficult to treat and clinical trials specifically targeting fistulising disease are particularly valuable.
Loading trials from ClinicalTrials.gov...